TAK-220 specifically binds to chemokine receptors. This binding blocks the receptors and prevents the corresponding chemokines from exerting their effects on immune cells, leading to reduced chemotaxis and cell activation. It targets HIV-1 (CTV), HIV-1 (CTV), HIV-1 (HHA), HIV-1 (HHA), HIV-1 (HKW), HIV-1 (HKW), HIV-1 (HNK), HIV-1 (HNK), HIV-1 (HTN), HIV-1 (HTN), HIV-1 (KK).
Molecular Weight
553.14
Molecular Formula
C31H41ClN4O3
Targets
HIV-1 (CTV): 0.72 nM (EC50, in PBMCs); HIV-1 (CTV): 5 nM (EC90, in PBMCs); HIV-1 (HHA): 0.55 nM (EC50, in PBMCs); HIV-1 (HHA): 4 nM (EC90, in PBMCs); HIV-1 (HKW): 1.7 nM (EC50, in PBMCs); HIV-1 (HKW): 12 nM (EC90, in PBMCs); HIV-1 (HNK): 1.7 nM (EC50, in PBMCs); HIV-1 (HNK): 28 nM (EC90, in PBMCs); HIV-1 (HTN): 0.93 nM (EC50, in PBMCs); HIV-1 (HTN): 15 nM (EC90, in PBMCs); HIV-1 (KK): 1.2 nM (EC50, in PBMCs)
Form
Lyophilized powder
Purity
≥98%
Identity
Confirmed by NMR/HPLC/MS.
Applications
TAK-220 is a CCR inhibitor studied for its effects on pathways involved in immune response and potential therapeutic applications.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
